Benjamin Chen

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

Diagnostics for the Real World (Europe) Ltd. develops diagnostic tests. The firm develops cutting-edge technologies and diagnostic assays for deployment in resource poor countries primarily through patient sample testing at the point of care or near the patient. Its signal amplification technologies offer rapid and reliable tests for Chlamydia, Hepatitis and HIV. The company was founded by Helen Lee in 2002 and is headquartered in Little Chesterford, the United Kingdom.

Diagnostics for the Real World (Europe) Ltd. develops diagnostic tests. The firm develops cutting-edge technologies and diagnostic assays for deployment in resource poor countries primarily through patient sample testing at the point of care or near the patient. Its signal amplification technologies offer rapid and reliable tests for Chlamydia, Hepatitis and HIV. The company was founded by Helen Lee in 2002 and is headquartered in Little Chesterford, the United Kingdom.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

Diagnostics for the Real World (Europe) Ltd. develops diagnostic tests. The firm develops cutting-edge technologies and diagnostic assays for deployment in resource poor countries primarily through patient sample testing at the point of care or near the patient. Its signal amplification technologies offer rapid and reliable tests for Chlamydia, Hepatitis and HIV. The company was founded by Helen Lee in 2002 and is headquartered in Little Chesterford, the United Kingdom.

Diagnostics for the Real World (Europe) Ltd. develops diagnostic tests. The firm develops cutting-edge technologies and diagnostic assays for deployment in resource poor countries primarily through patient sample testing at the point of care or near the patient. Its signal amplification technologies offer rapid and reliable tests for Chlamydia, Hepatitis and HIV. The company was founded by Helen Lee in 2002 and is headquartered in Little Chesterford, the United Kingdom.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.